News
-
-
-
PRESS RELEASE
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities remain listed and traded on Nasdaq as Jaguar announces regaining compliance with Nasdaq's bid price requirement. Updates on cancer supportive care drug crofelemer OnTarget trial results expected by July 23, 2024 -
-
-
-
-
-
PRESS RELEASE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health, Inc. to discuss updates on cancer supportive care portfolio in investor webcast, focusing on CTD and oral mucositis. Details on pivotal phase 3 OnTarget trial for crofelemer -